The ENDEAVOUR lung cancer program, a three-year initiative designed to advance lung cancer research and care by connecting early-career oncologists in Europe with internationally renowned experts in ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval our partner Jazz Pharmaceuticals received from the U.S. Food and Drug Administration in 2024 for Ziihera® ...

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in ...

UK pharma major AstraZeneca (LSE: AZN) is set to present data from more than 80 studies at the 2025 American Society of ...

The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...

Japan’s Nikkei share average fell to a two-week low on Thursday, tracking the sharp declines on Wall Street, while a spike in ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...

IHH's Singapore-based indirect subsidiary Northern TK Ventures (NTK) has approached the Tokyo District Court seeking to amend ...

The lawsuit pertains to damages arising from the alleged obstruction by Daiichi of NTK’s efforts to acquire shares in Fortis ...

IHH Healthcare’s indirect subsidiary, NTK, has filed an application with the Tokyo District Court to increase its ongoing ...